- Home
- ERAS vs KURA Comparison
ERAS vs KURA Comparison
Compare ERAS & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERAS | KURA |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ERAS | KURA |
|---|---|---|
| Price | $3.44 | $10.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $3.71 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 2.6M | 1.7M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $104,029,000.00 |
| Revenue This Year | N/A | $138.16 |
| Revenue Next Year | N/A | $66.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $5.41 |
| 52 Week High | $3.80 | $12.49 |
Technical Indicators
Market Signals| Indicator | ERAS | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 45.55 |
| Support Level | $3.36 | $9.68 |
| Resistance Level | $3.77 | $11.28 |
| Average True Range (ATR) | 0.24 | 0.53 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 40.77 | 31.77 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.